Clinical Trial

Real-World Study on the Burden of Hidradenitis Suppurativa

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Despite the significant impact of HS on patients' quality of life (QoL) and daily functioning, there remains limited real-world evidence describing the burden of this condition in Canada. HS is an under-recognized and often misdiagnosed condition, with a substantial psychological and physical burden on patients. Understanding the real-world experiences of individuals living with HS in Canada can help identify unmet needs and inform patient-centered care approaches.
Trial Details
NCT Number NCT07323303
Lead Sponsor PeriPharm
Conditions Hidradenitis Suppurativa (HS)
Enrollment 100 participants
Start Date 2026-01
Primary Completion 2026-06 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-07